Compound 2389
Identifiers
- Canonical SMILES:
CCOc1cc(ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@](C)(N1C(=O)N1CCN(CC1)C(C)=O)c1ccc(Cl)cc1)C(C)(C)C
- IUPAC name:
1-{4-[(4S,5R)-2-(4-tert-butyl-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethyl-4,5-dihydro-1H-imidazole-1-carbonyl]piperazin-1-yl}ethan-1-one
- InChi:
InChI=1S/C36H42Cl2N4O3/c1-8-45-31-23-27(34(3,4)5)13-18-30(31)32-39-35(6,25-9-14-28(37)15-10-25)36(7,26-11-16-29(38)17-12-26)42(32)33(44)41-21-19-40(20-22-41)24(2)43/h9-18,23H,8,19-22H2,1-7H3/t35-,36+/m0/s1
- InChiKey:
OHBOYVVVTREVDA-MPQUPPDSSA-N
External links
![]() 17754588 |
![]() CHEMBL2386343 |
External search
![]() |
![]() |
![]() |
![]() |
![]() |
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 3 | 1 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
MDM2-Like / P53 | 7.64 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 648.26 g/mol | |||
HBA | 7 | |||
HBD | 0 | |||
HBA + HBD | 7 | |||
AlogP | 7.37 | |||
TPSA | 65.45 | |||
RB | 6 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 3 | 1 | 0 |
Pharmacological data
Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity |
---|---|---|---|---|---|---|---|---|
10.1021/ml4000657 | 2d | MDM2 Q00987 |
P53 P04637 |
Biochemical assay | HTRF | pIC50 (half maximal inhibitory concentration, -log10) | 7.64 | |
10.1021/ml4000657 | 2d | MDM2 Q00987 |
P53 P04637 |
Cellular assay | MTT-assay | SJSA-1 | pIC50 (half maximal inhibitory concentration, -log10) | 6.52 |
10.1021/ml4000657 | 2d | MDM2 Q00987 |
P53 P04637 |
Cellular assay | MTT-assay | HCT-116 cells p53WT | pIC50 (half maximal inhibitory concentration, -log10) | 6.22 |
10.1021/ml4000657 | 2d | MDM2 Q00987 |
P53 P04637 |
Cellular assay | MTT-assay | RKO | pIC50 (half maximal inhibitory concentration, -log10) | 6.30 |
PK data
Bibliography | Name | Assay name | Administration mode | Dose (mg/kg) | Dose interval (hours) | Tolerated | AUC | Clearance | Cmax | Oral bioavailability | T1/2 (min) | Tmax (min) | Volume distribution (Vd) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
10.1021/ml4000657 | 2d | Mouse PK PO | PO | 50.00 | None | yes | yes | no | yes | None | 144 | None | no |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.9162 | Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone | DB04144 | |
0.9050 | RO-5045337 | DB14793 | |
0.8128 | Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone | DB02872 | |
0.3846 | Idanpramine | DB13276 | |
0.3843 | (6S)-2-amino-6-(3'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one | DB07874 | |
0.3803 | Atecegatran metoxil | DB12507 | |
0.3798 | Copanlisib | DB12483 | |
0.3777 | Sorbinil | DB02712 | |
0.3754 | PCO-371 | DB14946 | |
0.3746 | I-Coeleneterazine | DB04146 | |
0.3713 | Irbesartan | DB01029 | |
0.3704 | N-Coeleneterazine | DB04118 | |
0.3674 | Mazindol | DB00579 | |
0.3657 | PRI-724 | DB15034 | |
0.3656 | Timcodar | DB12761 |